Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

ABSTRACT:

Purpose

Co-administration of the 5α-reductase inhibitor dutasteride increases the oral testosterone bioavailability in men with experimentally induced hypogonadism. We examined oral testosterone with and without dutasteride administration in hypogonadal men for 28 days.

Materials and methods

We randomly assigned 43 hypogonadal men to twice daily oral doses of 150, 250 or 400 mg testosterone with 0.25 mg dutasteride, 400 mg testosterone alone or 0.25 mg dutasteride alone for 28 days in a multicenter study. Subjects underwent pharmacokinetic profiling of serum hormones on days 1 and 28. A total of 32 men completed all study procedures.

Results

Serum testosterone increased in all groups on testosterone compared with that in the dutasteride only group. At the 400 mg dose

SUBMITTER: Amory JK 

PROVIDER: S-EPMC4267472 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature